摘要
硫酸软骨素(CS)是一种糖胺聚糖(GAG),在双糖的积木式结构中由N-乙酰氨基半乳糖和葡萄糖醛酸单元交替组成。 CS 是软骨组织中蛋白多糖的关键功能成分。由于其众多的生物活性,CS在医药市场中被广泛应用作为为抗关节炎、骨关节病和骨质疏松症的营养成分。鲨鱼软骨和犊牛气管是软骨素原料的主要来源。尽管如此,在过去的几十年里,一种新型CS的医疗潜力已得到研究。并且,它被命名为岩藻糖硫酸软骨素 (FucCS). 这种较不常见的CS从海参的体壁中分离得到。在海参FucCS中岩藻糖基分支单位的存在使得其在不同的病理生理学系统中有着独特的GAG和治疗特性。已经应用于市场的常见的CS并不存在这些性质。这些系统的例子有凝血、血栓形成、血液透析、动脉粥样硬化、细胞生长、血管生成、纤维化、肿瘤生长、炎症、病毒和原虫感染、高血糖、糖尿病相关的病理过程和组织损伤。本文目的在于讨论了CS岩藻糖基化的医疗优势并探讨了这些优势的临床应用前景。
关键词: 碳水化合物药物发现,碳水化合物药物开发,硫酸软骨素,岩藻糖,岩藻糖硫酸软骨素,糖胺聚糖。
Current Medicinal Chemistry
Title:Medical Gains of Chondroitin Sulfate Upon Fucosylation
Volume: 22 Issue: 36
Author(s): Vitor H. Pomin
Affiliation:
关键词: 碳水化合物药物发现,碳水化合物药物开发,硫酸软骨素,岩藻糖,岩藻糖硫酸软骨素,糖胺聚糖。
摘要: Chondroitin sulfate (CS) is a glycosaminoglycan (GAG) composed of alternating N-acetyl galactosamine and glucuronic acid units within disaccharide building blocks. CS is a key functional component in proteoglycans of cartilaginous tissues. Owing to its numerous biological roles, CS is widely explored in the pharmaceutical market as nutraceutical ingredient commonly utilized against arthritis, osteoarthrosis, and sometimes osteoporosis. Tissues like shark cartilage and bovine trachea are common sources of CS. Nonetheless, a new CS type has been introduced and investigated in the last few decades in what regards its medical potentials. It is named fucosylated chondroitin sulfate (FucCS). This less common CS type is isolated exclusively from the body wall of sea cucumbers. The presence of fucosyl branching units in the holothurian FucCS gives to this unique GAG, therapeutic properties in various pathophysiological systems which are inexistent in the common CS explored in the market. Examples of these systems are coagulation, thrombosis, hemodialysis, atherosclerosis, cellular growth, angiogenesis, fibrosis, tumor growth, inflammation, viral and protozoan infections, hyperglycemia, diabetes-related pathological events and tissue damage. This report aims at describing the medical benefits gained upon fucosylation of CS. Clinical prospects of these medical benefits are also discussed herein.
Export Options
About this article
Cite this article as:
Vitor H. Pomin , Medical Gains of Chondroitin Sulfate Upon Fucosylation, Current Medicinal Chemistry 2015; 22 (36) . https://dx.doi.org/10.2174/0929867322666151020101335
DOI https://dx.doi.org/10.2174/0929867322666151020101335 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians 2016 Guidelines
Current Drug Metabolism The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design The Pharmacological Management of Delirium in Critical Illness
Current Drug Therapy State of the Art Management of Transfusion-Related Acute Lung Injury (TRALI)
Current Pharmaceutical Design Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Vascular Endothelium and Hypovolemic Shock
Current Vascular Pharmacology Nutraceuticals - An Emerging Era in the Treatment and Prevention of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Pathophysiology of Myocardial Infarction and Acute Management Strategies
Cardiovascular & Hematological Agents in Medicinal Chemistry Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology A New Phospholipase A<sub>2</sub> from Lachesis <i>muta rhombeata</i>: Purification, Biochemical and Comparative Characterization with Crotoxin B
Protein & Peptide Letters